34771-04-5Relevant articles and documents
Tricyclic compound and JAK inhibitor
-
, (2016/11/24)
Provided is a novel tricyclic compound which has JAK inhibitory activity and is especially useful for prophylaxis, treatment or amelioration of autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic compound which is represented by formula (I), formula (II) or formula (III) (wherein each of A1, A2 and A3 represents a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 represents a methylene group or the like; each of X1 and X3 represents O or NH; each of R1 and R3 represents a cyano C1-6 haloalkyl group or the like; and R2 represents an aromatic heterocyclic group), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer or the pharmaceutically acceptable salt.
TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR
-
, (2016/01/01)
To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.